Press release
Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline: 25+ Leading Companies Driving Innovation with Next-Generation Therapies | DelveInsight
The Extensive-Stage small cell lung cancer market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics, and Biotheus. These industry pioneers are transforming treatment strategies and redefining the future of Extensive-Stage Small Cell Lung Cancer, bringing new hope to patients worldwide.DelveInsight's "Extensive-Stage Small Cell Lung Cancer Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Extensive-Stage Small Cell Lung Cancer market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
For emerging Extensive-Stage small cell lung cancer drugs, the Extensive-Stage Small Cell Lung Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Extensive-Stage Small Cell Lung Cancer Pipeline Report
• DelveInsight's Extensive-Stage small cell lung cancer pipeline analysis depicts a robust space with 25+ active players working to develop 30+ pipeline drugs for Extensive-Stage Small Cell Lung Cancer treatment.
• The leading Extensive-Stage Small Cell Lung Cancer companies include Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC, and others are evaluating their lead assets to improve the Extensive-Stage Small Cell Lung Cancer treatment landscape.
• Key Extensive-Stage Small Cell Lung Cancer pipeline therapies in various stages of development include ABP-745, SHR4640, SEL-212, LC350189, SAP-001, AC-201, Dapansutrile, URC-102, Bucillamine, HP501, AR882, DYV700, ABP-671, Anakinra, ALLN-346, TMX-049, Verinurad, RPH-104, D-0120, and others.
• In January 2025, Zai Lab Limited announced that the FDA granted Orphan Drug Designation (ODD) to ZL-1310, a first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).
• In January 2025, Amgen announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorisation to IMDYLLTRA® for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after at least two prior lines of therapy, including platinum-based chemotherapy.
• In January 2025, BridgeBio Oncology Therapeutics (BBOT) announced that the FDA granted Fast Track designation to BBO-8520, an investigational oral therapy for treating adult patients with previously treated, KRASG12C-mutated metastatic non-small cell lung cancer (NSCLC).
• In December 2024, Gilead Sciences announced that the FDA granted Breakthrough Therapy Designation to TRODELVY® (sacituzumab govitecan-hziy) for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed after platinum-based chemotherapy.
• In August 2024, AstraZeneca's supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) was accepted and granted Priority Review in the US, based on positive results from the ADRIATIC Phase III trial in patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed after platinum-based concurrent chemoradiotherapy (cCRT).
Request a sample and discover the recent breakthroughs happening in the Extensive-Stage small cell lung cancer pipeline landscape @ https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Extensive-Stage Small Cell Lung Cancer Overview
Extensive-Stage small cell lung cancer is an aggressive and fast-growing type of lung cancer that accounts for 10-15% of all lung cancer cases and is strongly linked to smoking. Unlike non-small cell lung cancer (NSCLC), ESCLC spreads rapidly beyond the lungs, often reaching the brain, liver, bone marrow, and adrenal glands. Common symptoms include persistent cough, chest pain, shortness of breath, and systemic signs like weight loss and fatigue. Paraneoplastic syndromes such as SIADH, Cushing's syndrome, or Lambert-Eaton syndrome may also occur.
The disease is primarily caused by prolonged tobacco use and is driven by mutations in tumor suppressor genes like TP53 and RB1. It originates from neuroendocrine cells in the lungs, which proliferate rapidly and metastasize early.
Diagnosis involves imaging (CT, PET scans) and biopsy (via bronchoscopy or needle sampling). Due to its extensive spread, systemic therapy is the cornerstone of treatment. Chemotherapy-commonly cisplatin or carboplatin with etoposide-remains the standard, often combined with immunotherapy agents such as atezolizumab or durvalumab. Radiation is used selectively for symptom relief or combined with other treatments.
Despite advances, ESCLC has a poor prognosis, with median survival of 6-12 months. Research continues to focus on improving treatment outcomes.
Find out more about Extensive-Stage small cell lung cancer medication @ https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Extensive-Stage Small Cell Lung Cancer Treatment Analysis: Drug Profile
Serplulimab + Chemotherapy (Shanghai Henlius Biotech)
Serplulimab, an anti-PD-1 monoclonal antibody, is being evaluated in combination with chemotherapy for the treatment of several cancers, including esophageal squamous cell carcinoma (ESCC), extensive-stage small cell lung cancer (ES-SCLC), and gastric cancer (GC). The drug is currently in Phase III development for ES-SCLC. Shanghai Henlius Biotech is also conducting global, multi-center Phase III trials for squamous non-small cell lung cancer (sqNSCLC), ES-SCLC, and limited-stage SCLC (LS-SCLC). Fast-track Phase III studies are ongoing for neoadjuvant/adjuvant GC and LS-SCLC.
Vobramitamab Duocarmazine (MGC018) - MacroGenics, Inc.
Vobramitamab duocarmazine (MGC018) is an investigational antibody-drug conjugate (ADC) that targets B7-H3, a protein commonly overexpressed in solid tumors. It consists of a humanized B7-H3 monoclonal antibody linked to the prodrug DUBA (a potent DNA-alkylating agent), with a drug-to-antibody ratio of approximately 2.7. DUBA induces DNA damage in both proliferating and non-proliferating cells, leading to cell death. MGC018 is currently in Phase II development for the treatment of extensive-stage small cell lung cancer (ESCLC).
Key Extensive-Stage Small Cell Lung Cancer Therapies and Companies
• Serplulimab+Chemo: Shanghai Henlius Biotech
• Vobramitamab duocarmazine (MGC018): MacroGenics, Inc.
• RYZ101: RayzeBio, Inc.
• IMDYLLTRA: Amgen
• BBO-8520: BridgeBio Oncology Therapeutics
• ZL-1310: Zai Lab Limited
• Trodelvy: Gilead Sciences
• IMFINZI: AstraZeneca
Learn more about the novel and emerging Extensive-Stage small cell lung cancer pipeline therapies @ https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Extensive-Stage Small Cell Lung Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.
By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Scope of the Extensive-Stage Small Cell Lung Cancer Pipeline Report
• Coverage: Global
• Key Extensive-Stage Small Cell Lung Cancer Companies: Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, Inc., Genentech, Eli Lilly and Company, Amgen, Hutchison Medipharma Limited, Biocity Biopharmaceutics Co., Ltd., Biotheus Inc., GSK, InxMed (Shanghai) Co., Ltd., Daiichi Sankyo, Merck Sharp & Dohme LLC,, and others.
• Key Extensive-Stage Small Cell Lung Cancer Pipeline Therapies: ABP-745, SHR4640, SEL-212, LC350189, SAP-001, AC-201, Dapansutrile, URC-102, Bucillamine, HP501, AR882, DYV700, ABP-671, Anakinra, ALLN-346, TMX-049, Verinurad, RPH-104, D-0120, and others.
Dive deep into rich insights for drugs used for Extensive-Stage small cell lung cancer treatment; visit @ https://www.delveinsight.com/report-store/extensive-stage-small-cell-lung-cancer-esclc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr
Table of Contents
1. Introduction
2. Executive Summary
3. Extensive-Stage Small Cell Lung Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Extensive-Stage Small Cell Lung Cancer Pipeline Therapeutics
6. Extensive-Stage Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
7. Extensive-Stage Small Cell Lung Cancer Pipeline: Late-Stage Products (Phase III)
8. Extensive-Stage Small Cell Lung Cancer Pipeline: Mid-Stage Products (Phase II)
9. Extensive-Stage Small Cell Lung Cancer Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix
Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Extensive-Stage Small Cell Lung Cancer (ESCLC) Pipeline: 25+ Leading Companies Driving Innovation with Next-Generation Therapies | DelveInsight here
News-ID: 3963664 • Views: …
More Releases from DelveInsight

Lung Adenocarcinoma Clinical Trials Analysis 2025: Targeted Therapies, Immunothe …
DelveInsight's "Lung Adenocarcinoma - Clinical Trials Analysis, 2025" describes a dynamic and fast-moving development landscape focusing on two complementary goals: (1) inhibit tumor growth and progression through targeted and immune-based therapies, and (2) improve patient survival, quality of life, and functional outcomes. Current programs include EGFR, ALK, KRAS, and MET inhibitors, immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4), and emerging bispecific antibodies and combination regimens designed to overcome resistance and enhance efficacy.
Late-stage…

Neurofibromatosis Type 1 Clinical Trials Analysis 2025: Targeted RAS-Pathway and …
The Neurofibromatosis Type 1 (NF1) clinical trial landscape in 2025 focuses on two main goals: controlling plexiform and cutaneous neurofibromas and preventing malignant peripheral nerve sheath tumors (MPNST) while improving quality of life. Current programs include RAS-MAPK pathway inhibitors, next-generation MEK inhibitors, mTOR modulators, immuno-oncology agents for MPNST, and early gene-directed therapies.
Late-stage trials primarily test oral RAS pathway inhibitors for pediatric plexiform neurofibromas, with attention to safety, functional improvement, and…

Neisseria Meningitidis Meningitis Clinical Trials Analysis 2025: Multivalent Vac …
DelveInsight's "Neisseria Meningitidis Meningitis - Clinical Trials Analysis, 2025" outlines a rapidly evolving landscape aimed at two primary goals: (1) provide broad serogroup coverage through next-generation multivalent and protein-based vaccines, and (2) improve long-term immunity and reduce disease incidence in adolescents, young adults, and high-risk populations. Ongoing programs include conjugate vaccines, adjuvanted formulations, and combination vaccines targeting meningococcal and other pediatric pathogens to optimize immunization schedules.
Late-stage and pivotal trials focus…

Essential Tremor Clinical Trials Analysis 2025: Novel Pharmacologics, Neuromodul …
DelveInsight's "Essential Tremor - Clinical Trials Analysis, 2025" highlights a dynamic development landscape focused on two complementary goals: (1) reduce tremor severity and improve motor control, and (2) enhance patient quality of life and daily functioning. Ongoing programs include small-molecule pharmacologics targeting GABAergic and calcium channel pathways, focused ultrasound neuromodulation, deep brain stimulation (DBS) refinements, and emerging gene therapy candidates aimed at long-term tremor suppression.
Late-stage and registration-enabling trials assess efficacy,…
More Releases for Stage
ReggaeEDM Takes The Stage
By Luke W. Archer
1998 Zen Fest, Zephyrhills, FL.
Sweat and steam spread a misty haze above a sea of anticipating ravers. It had rained that day, in fact, it was raining outside now, a fitting stage for the dreamlike haze that filled his mind. Hiding any hint of nervousness behind thick glasses, he followed his entourage of backbeat dancers and musical alchemists onto the smoke-filled DJ stage. The crowd erupted like…
Consciousness on stage: Spiritual teacher and entrepreneur shines on stage
Wiesbaden 13.3.2025 - Heidi Krauss from Konstanz, Managing Director of the Mindfeed Institute, based in Untersteinach, and founder of Akawa, took part in the International Speaker Slam in Wiesbaden and wowed the audience with her message of personal development and understanding form and formlessness. The event, which attracted 230 participants from 28 countries, provided a stage for inspiring speakers from all over the world.
Krauss, an expert in the field of…
Future-Proofing Growth Stage Lighting Construction Service Market, Size, Analyti …
The latest market intelligence report published by WMR with the title "Global Stage Lighting Construction Service Market 2024, Growth Opportunities, and Forecast" provides actionable insights on Manufacturing and Construction industry. The report provides demand analysis, industry insights, competitive intelligence, and customer database.
The Research report on Stage Lighting Construction Service Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y…
Portable Adjustable Stage Market 2022 Analysis by Top Leading Players | Mega Sta …
The global Portable Adjustable Stage Market study provides a comprehensive examination of the market throughout the projection quantity. The study covers an expansion of sections likewise as associate analysis of the events and factors that area unit probably to play a serious role at intervals the long run. These elements, referred to as market dynamics, embrace the drivers, restrictions, options, and difficulties that type the image of those elements. The market's intrinsic…
LED Stage Lighting Market Size And Forecast | ETC (Electronic Theatre Controls), …
New Jersey, United States - The research study offers an in-depth assessment of the LED Stage Lighting Market and helps market players to gain a foothold in the industry. It highlights critical market dynamics such as drivers, restraints, trends, and opportunities to help businesses prepare for the challenges ahead. It provides a regional analysis of the LED Stage Lighting market to uncover major opportunities available in different parts of the…
LED Stage Lighting Market World's Top Players Include Colorful Light (HK) Limite …
Worldwide Market Reports has announced the addition of the “Global LED Stage Lighting Market Size, Status and Forecast 2025”, Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business.
Get Access to Sample Copy @ https://www.worldwidemarketreports.com/sample/134710
This report studies the LED Stage Lighting Production market status and outlook of global and United States, from angles…